NCT04599426 is a Phase 1, PHASE2 clinical trial of Allogeneic NK cell regimen group in MDS-EB, sponsored by The Second Hospital of Shandong University.

Who is sponsoring NCT04599426?

NCT04599426 is sponsored by The Second Hospital of Shandong University.

What drugs are being tested in NCT04599426?

Interventions in NCT04599426: Allogeneic NK cell regimen group.

Is NCT04599426 still recruiting?

NCT04599426 is currently status unknown. Last updated 22 October 2020.

Last reviewed 2020-10-22 · How we verify

NCT04599426

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogenic NK Cell Transfusion Azacitidine MDS-EB

Status unknown Phase 1, PHASE2 Last updated 22 October 2020

What this trial tests

Phase 1, PHASE2 trial testing Allogeneic NK cell regimen group in MDS-EB in 10 participants. Status unknown.

Timeline

1 December 2020

Primary endpoint
30 December 2023

30 December 2023

Quick facts

Lead sponsor	The Second Hospital of Shandong University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 December 2020
Primary completion	30 December 2023
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

Allogeneic NK cell regimen group — full drug profile →

Conditions studied

MDS-EB — all drugs for MDS-EB →

Sponsor

The Second Hospital of Shandong University

Who can join

Adults 15 to 70, any sex, with MDS-EB. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for refractory MDS-EB.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Allogeneic NK cell regimen group

Trials testing the same drug.

NCT04599452 — NK Cell Therapy Recurrent/Refractory Elderly AML · Phase 1, PHASE2 · unknown

Other The Second Hospital of Shandong University trials

Trials by the same sponsor.

NCT07430579 — Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma · NA · recruiting
NCT06337968 — CPB for Arthroscopic Hip Surgery · NA · not yet recruiting
NCT06604091 — Cohort Profile：The Shandong Adenomyosis Cohort of Population Undergoing Reproductive Technology (SAart) · active not recruiting
NCT06574958 — Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma · EARLY_PHASE1 · active not recruiting
NCT06572956 — Clinical Study on the Safety and Efficacy of CAR-T/CAR-NK Cells in the Treatment of Recurrent Refractory or Unresectable · EARLY_PHASE1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04599426 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Second Hospital of Shandong University
Last refreshed: 22 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04599426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing